Genetic vaccination against experimental infection with myotropic parasite strains of Trypanosoma cruzi
Authors
Araujo, Adriano Fernandode Oliveira, Gabriel
Vasconcelos, Juliana Fraga
Ersching, Jonatan
Dominguez, Mariana Ribeiro
Vasconcelos, Jose Ronnie
Machado, Alexandre Vieira
Gazzinelli, Ricardo T.
Bruna-Romero, Oscar
Soares, Milena Botelho
Rodrigues, Mauricio Martins
UMass Chan Affiliations
Department of Medicine, Division of Infectious Diseases and ImmunologyDocument Type
Journal ArticlePublication Date
2014-06-26Keywords
AnimalsCD8-Positive T-Lymphocytes
Chagas Disease
Female
Glycoproteins
Interleukin-12
Male
Mice
Mice, Inbred BALB C
Neuraminidase
Trypanosoma cruzi
Genetics and Genomics
Immunology and Infectious Disease
Immunoprophylaxis and Therapy
Parasitic Diseases
Parasitology
Metadata
Show full item recordAbstract
In earlier studies, we reported that a heterologous prime-boost regimen using recombinant plasmid DNA followed by replication-defective adenovirus vector, both containing Trypanosoma cruzi genes encoding trans-sialidase (TS) and amastigote surface protein (ASP) 2, provided protective immunity against experimental infection with a reticulotropic strain of this human protozoan parasite. Herein, we tested the outcome of genetic vaccination of F1 (CB10XBALB/c) mice challenged with myotropic parasite strains (Brazil and Colombian). Initially, we determined that the coadministration during priming of a DNA plasmid containing the murine IL-12 gene improved the immune response and was essential for protective immunity elicited by the heterologous prime-boost regimen in susceptible male mice against acute lethal infections with these parasites. The prophylactic or therapeutic vaccination of resistant female mice led to a drastic reduction in the number of inflammatory infiltrates in cardiac and skeletal muscles during the chronic phase of infection with either strain. Analysis of the electrocardiographic parameters showed that prophylactic vaccination reduced the frequencies of sinus arrhythmia and atrioventricular block. Our results confirmed that prophylactic vaccination using the TS and ASP-2 genes benefits the host against acute and chronic pathologies caused by T. cruzi and should be further evaluated for the development of a veterinary or human vaccine against Chagas disease.Source
Mediators Inflamm. 2014;2014:605023. doi: 10.1155/2014/605023. Epub 2014 Jun 26. Link to article on publisher's siteDOI
10.1155/2014/605023Permanent Link to this Item
http://hdl.handle.net/20.500.14038/39726PubMed ID
25061263Related Resources
Link to Article in PubMedRights
This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Distribution License
http://creativecommons.org/licenses/by/3.0/ae974a485f413a2113503eed53cd6c53
10.1155/2014/605023
Scopus Count
Collections
Except where otherwise noted, this item's license is described as <p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p>